Clinical impact of selumetinib on pediatric elephantiasis neuromatosa-Reference-Cited by-同舟云学术

Clinical impact of selumetinib on pediatric elephantiasis neuromatosa

Published:2022-06-23 Issue:5 Volume:39 Page:764-766
ISSN:0736-8046
Container-title:Pediatric Dermatology
language:en
Short-container-title:Pediatric Dermatology

Author:

Blegen Kristina¹^ORCID,Ortiz‐Romero Sara E.²,Juarez Olivia³,Voeller Julie⁴^ORCID

Affiliation:

1. Department of Pediatrics Baylor College of Medicine, The Children's Hospital of San Antonio San Antonio Texas USA

2. Department of Radiology Baylor College of Medicine, The Children's Hospital of San Antonio San Antonio Texas USA

3. Department of Genetics Baylor College of Medicine, The Children's Hospital of San Antonio San Antonio Texas USA

4. Department of Hematology Oncology Baylor College of Medicine, The Children's Hospital of San Antonio San Antonio Texas USA

Publisher

Wiley

Subject

Dermatology,Pediatrics, Perinatology and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/pde.15044

Reference5 articles.

1. AstraZenecaKoselugo (selumetinib). Accessed April 2 2022.https://www.koselugohcp.com/about.html

2. U.S. Food & Drug AdministrationFDA approves selumetinib for neurofibromatosis type 1 with symptomatic inoperable plexiform neurofibromas. 2020. Accessed April 2 2022.https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selumetinib-neurofibromatosis-type-1-symptomatic-inoperable-plexiform-neurofibromas

3. Selumetinib in Children with Inoperable Plexiform Neurofibromas

4. Massive Soft Tissue Neurofibroma (Elephantiasis Neuromatosa)

5. NF1 truncating mutations associated to aggressive clinical phenotype with elephantiasis neuromatosa and solid malignancies;Ponti G;Anticancer Res,2014

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Limb Hypertrophy—An Uncommon Presentation Yet a Common Link among Neurocutaneous Syndromes: A Series of Three Cases;Journal of Pediatric Neurology;2022-12-30